Dose-finding, Pharmacokinetics, and Safety of VABOMERE in Pediatric Subjects With Bacterial Infections
Completed · Phase 1 · NCT02687906
Conditions: Bacterial Infections
At a glance
- Research payments reported, 2025
- $13,054
- U.S. investigators named
- 3
- Sites paid
- 3
- Planned or actual enrollment
- 39
About the trial
- Sponsor
- Rempex (a wholly owned subsidiary of Melinta Therapeutics, LLC) (with Department of Health and Human Services)
- Tested
- Vabomere (drug)
- Dates
- Started 2016-07; completion 2026-07-15
- Results posted
- Not yet
A single dose infusion of Vabomere (meropenem-vaborbactam) is being tested for dose-finding, pharmacokinetics, safety, and tolerability in pediatric subjects from birth to less than 18 years of age with serious bacterial infections
From ClinicalTrials.gov, last updated 2026-08-17. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Melinta Therapeutics, LLC reported $13,054 in research payments for this study in 2025 (9 payments).
Products named: Vabomere
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- John S. Bradley, M.D. Pediatric Infectious Disease · San Diego, CA
- William J. Muller, MD, PHD Pediatric Infectious Disease · Chicago, IL
- James B. Deville, MD Cardiac Electrophysiology · Plano, TX
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- University of California, San Diego $4,713
- Ann & Robert H Lurie Childrens Hospital of Chicago, IL $4,681
- $2,400
- Lundquist Institute for Biomedical Innovation at Harbor-UCLA $1,260
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.